Press Releases September 8, 2026 08:00 AM

Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Fortress Biotech to present corporate overview at H.C. Wainwright Annual Global Investment Conference

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
FBIO

Fortress Biotech, an innovative biopharmaceutical company focused on advancing assets and expanding its product portfolio in oncology, dermatology, and rare diseases, announced that its CEO Lindsay A. Rosenwald will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The company will also engage in one-on-one meetings during the conference.

Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
FBIO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Fortress Biotech is presenting its corporate strategy and portfolio overview at a major investment conference.
  • The company has a diverse portfolio including marketed prescription products and development programs in various therapeutic areas such as oncology, dermatology, and rare diseases.
  • Fortress Biotech maintains strategic partnerships with leading academic and biopharmaceutical institutions to develop and commercialize its assets.

MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation will be available for on-demand viewing by conference attendees starting on Friday, September 11, 2026, at 7:00 a.m. ET. The Company will also attend one-on-one meetings during the conference taking place September 14-16, 2026.

About Fortress Biotech 
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Center and Sentynl Therapeutics. For more information, visit www.fortressbiotech.com.

Company Contact:
Jaclyn Jaffe
Fortress Biotech, Inc.
(781) 652-4500
[email protected]

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
[email protected]  


Risks

  • The presentation itself does not reveal new clinical or financial data that could immediately impact stock performance.
  • The success of Fortress Biotech's portfolio depends on the progress and regulatory approval of its drug candidates, which remain uncertain.
  • Partnerships with academic and pharmaceutical entities may face challenges or delays that could impact commercialization timelines.

More from Press Releases

Barfresh Receives USDA Re-Approval of $2.4 Million Grant Following Updated Facility Design, Equipment and Installation Requirements Sep 8, 2026 BOS to Present at Sidoti’s Small-Cap Virtual Investor Conference September 23-24, 2026 Sep 8, 2026 Trust Stamp Collaborates with Jack Henry® to Combat Sophisticated Identity Fraud with Government-Backed DMV Data Verification Sep 8, 2026 Kodiak AI On Track For Year-End Driverless Long-Haul Launch as Safety Case Readiness Reaches 93% Sep 8, 2026 T3 Defense Targets Accelerating European Demand for Air Defense Ground-System Components Sep 8, 2026